

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 66388

**Title:** Endothelial progenitor cells and coronary artery disease: current concepts and the future research directions

**Reviewer's code:** 04738361

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Director, Research Scientist

**Reviewer's Country/Territory:** France

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-03-26

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-09 08:39

**Reviewer performed review:** 2021-04-13 09:32

**Review time:** 4 Days

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

This manuscript describes endothelial progenitor cells in the context of coronary artery disease. The authors have discussed different cell markers and their functions. Although this is an interesting manuscript, the following point should be clarified before its publication. \* Please add page and line numbers. \*The authors have truly mentioned that currently, no specific endothelial marker exists to distinguish EPCs from the rest of endothelial cells, however, recent findings mostly through bioinformatic analysis reported some dissimilarities among ECs. The following article could help you build this section. PMID: 33627177 \* Regarding the comparison between mature and immature ECs, the authors have to discuss their newly reported immunological differences. It has been shown that, unlike HAECs, EPCs from both cord blood and adult peripheral blood sources are immunosuppressive against T cells and can regulate them. This manuscript lacks immunological discussions. The following articles can help you to cover this domain. PMID: 32546175, PMID: 33397378 \*The authors have mentioned that the expression of CD146 was related to endothelial dysfunction. However, they have mentioned another study using CD146 to capture EPCs on stents. Please discuss the controversial role of this marker and its applications. \* The authors do not describe the role of CD31 anywhere in the text.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 66388

**Title:** Endothelial progenitor cells and coronary artery disease: current concepts and the future research directions

**Reviewer's code:** 04738361

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Director, Research Scientist

**Reviewer's Country/Territory:** France

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-03-26

**Reviewer chosen by:** Yun-Xiaojian Wu

**Reviewer accepted review:** 2021-06-15 09:32

**Reviewer performed review:** 2021-06-15 09:37

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

The authors have clearly answered my concerns, I have no further comments.